Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

por Le Tourneau, C, Servois, V, Diéras, V, Ollivier, L, Tresca, P, Paoletti, X
Publicado 2012

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

por Eskens, F A L M, Tresca, P, Tosi, D, Van Doorn, L, Fontaine, H, Van der Gaast, A, Veyrat-Follet, C, Oprea, C, Hospitel, M, Dieras, V
Publicado 2014

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

por Brain, E, Isambert, N, Dalenc, F, Diéras, V, Bonneterre, J, Rezai, K, Jimenez, M, Mefti-Lacheraf, F, Cottura, E, Tresca, P, Vanlemmens, L, Mahier-Aït Oukhatar, C, Lokiec, F, Fumoleau, P
Publicado 2012

Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial

por de Guillebon, E., Jimenez, M., Mazzarella, L., Betsou, F., Stadler, P., Peták, I., Jeannot, E., Chanas, L., Servant, N., Marret, G., Duso, B.A., Legrand, F., Kornerup, K.N., Bernhart, S.H., Balogh, G., Dóczi, R., Filotás, P., Curigliano, G., Bièche, I., Guérin, J., Dirner, A., Neuzillet, C., Girard, N., Borcoman, E., Larbi Chérif, L., Tresca, P., Roufai, D.B., Dupain, C., Scholl, S., André, F., Fernandez, X., Filleron, T., Kamal, M., Le Tourneau, C.
Publicado 2021